Cocrystal Pharma (NASDAQ:COCP – Get Free Report) announced its earnings results on Monday. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.23, Zacks reports.
Cocrystal Pharma Stock Down 1.1 %
Shares of NASDAQ COCP opened at $1.46 on Monday. Cocrystal Pharma has a 12 month low of $1.35 and a 12 month high of $3.26. The company has a market cap of $14.89 million, a price-to-earnings ratio of -0.79 and a beta of 2.35. The business has a fifty day simple moving average of $1.81 and a 200-day simple moving average of $1.93.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Cocrystal Pharma in a research report on Wednesday, January 22nd.
About Cocrystal Pharma
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Featured Articles
- Five stocks we like better than Cocrystal Pharma
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- AT&T and Verizon: 2 Telecom Titans for a Tariff-Proof Play
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 High-Performing Tech ETFs to Diversify Your Portfolio
- What is a Stock Market Index and How Do You Use Them?
- Netflix Poised for Significant Rally as a Safe Haven Stock
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
